TSW
VIR icon

Thompson Siegel & Walmsley’s Vir Biotechnology VIR Stock Holding History

Thompson Siegel & Walmsley’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$846K Sell
83,000
-9,000
-10% -$85.6K 0.02% 333
2026
Q1 		$824K Buy
+92,000
New +$733K 0.01% 328

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Thompson Siegel & Walmsley's VIR Position: Q2 2026 in Review

Thompson Siegel & Walmsley reduced its Vir Biotechnology (VIR) stake by 9.8% in Q2 2026, selling an estimated $85.6K and leaving 83,000 shares worth $846K. The position accounts for 0.02% of the portfolio, ranked #333.

Thompson Siegel & Walmsley first reported a position in VIR in Q1 2026 and has held it in 2 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Thompson Siegel & Walmsley held 83,000 shares of Vir Biotechnology worth $846K as of Q2 2026.
  • Thompson Siegel & Walmsley sold 9,000 Vir Biotechnology shares in Q2 2026, an estimated $85.6K.
  • Vir Biotechnology made up 0.02% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #333 holding.
  • Thompson Siegel & Walmsley first reported a position in Vir Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.